US-based contract research organisation (CRO) Charles River Laboratories International is expecting revenue growth in the range of 10%-13% next year, including a boost of around 1% from foreign exchange.

Issuing guidance for 2008, the CRO said its Preclinical Services segment should grow “at a low- to mid-teens rate”, benefiting from strong demand for outsourced development services and the addition of new capacity. The outlook for Research Models and Services is less favourable, although the segment is still expected to grow at “a high single-digit” rate next year, driven especially by gains from the North American research models, research model services and In Vitro businesses.

Earnings per diluted share for 2008 are projected at $2.59-$2.69. Looked at in terms of continuing operations, which excludes around $0.28 per diluted share in amortisation of intangible assets related to acquisitions, earnings per diluted share are forecast at between $2.87 and $2.97, roughly 11%-15% higher than the expected figures for 2007.

Charles River has maintained the improved guidance for the current year that it issued with its third-quarter results, including expected sales growth of 14%-16%.